Back to blog

Testosterone and Male Health: What a Systematic Review Can—and Cannot—Tell Us

A 2023 PubMed Central systematic review examines how testosterone relates to men's health, from sexual function to cardiovascular risk. We outline where the evidence is stronger or weaker, how to read lab results, and what remains uncertain.

Testosterone and Male Health: What a Systematic Review Can—and…

Key idea

Testosterone affects many aspects of male health, including sexual function, mood, body composition, and bone. A 2023 PubMed Central systematic review titled “Impact of Testosterone on Male Health: A Systematic Review” looks across multiple studies to weigh potential benefits and risks. Systematic reviews lower bias by combining evidence, but they cannot remove all uncertainty.

This article is educational and not medical advice. Testing and treatment decisions should be made with a qualified clinician.

Why this matters

As some men experience age-related declines in testosterone, interest in testing and therapy rises. Public discussion can swing from cure-all claims to blanket warnings. A systematic review helps clarify where benefits are plausible, where risks may outweigh gains, and where results depend on context—such as baseline levels, symptoms, age, other health conditions, and goals of care.

How the review approach works (and its limits)

Systematic reviews use predefined methods to search for, select, and appraise studies. They can reveal patterns across research, but their conclusions depend on which studies are included and how outcomes are measured. The public record we accessed does not list sample sizes, effect sizes, or follow-up durations for this review, so we do not make numerical claims and focus on interpretation principles instead.

Outcomes commonly assessed

  • Sexual symptoms: libido, erectile function, and sexual activity.
  • Mood and energy: depressive symptoms and fatigue.
  • Body composition and bone: changes in muscle mass, fat mass, and bone density.
  • Metabolic markers: insulin resistance and blood lipids (lab numbers that may not equal better health outcomes).
  • Cardiovascular events: heart attack, stroke, and hospitalizations (rare outcomes need very large, long studies).
  • Blood effects: high red blood cell count (high hematocrit), which can thicken the blood.
  • Prostate measures: prostate size, urinary symptoms, and prostate-specific antigen (PSA, a blood test).
  • Fertility: effects on sperm production and the ability to conceive.
  • Sleep and breathing: obstructive sleep apnea (breathing pauses during sleep).

Measurement basics that shape interpretation

  • Timing matters. Testosterone is usually higher in the morning. Illness, poor sleep, and stress can shift levels. One test is rarely definitive; repeating a morning test improves accuracy.
  • Total vs. free testosterone. Free testosterone is the portion not bound to proteins. Sex hormone–binding globulin (SHBG), a protein that carries testosterone, affects the free fraction.
  • Lab variability. Different assays and lab runs can give slightly different results. This reduces comparability across studies and over time.

These issues help explain why individual studies—and reviews that pool them—do not always align.

What may be changing in our understanding

  • Some outcomes (for example, sexual symptoms) may show clearer signals than others.
  • The balance of benefit and risk can differ by context—men with consistent symptoms and repeatedly low levels may differ from those with borderline values and few symptoms.
  • Changes in lab surrogates (like lipids) do not guarantee improvements in how people feel or in long-term event risk.

Because the public summary for this review lacks quantitative results, we avoid implying specific effect sizes.

What this means in everyday decisions

  • Symptoms and numbers are not the same thing. A diagnosis of testosterone deficiency usually requires both symptoms and repeatedly low levels; thresholds vary by guideline.
  • Context drives trade-offs. Where benefits occur, they are likelier in men with clear symptoms and low levels; in asymptomatic men with borderline values, net benefit is less certain.
  • Safety monitoring matters. In clinical settings, follow-up can include hematocrit (red cell concentration), PSA, urinary symptoms, blood pressure, and sleep changes to catch adverse effects early.
  • Fertility is separate. External testosterone can suppress sperm production, which matters for those planning to conceive.
  • Lifestyle and medications count. Excess body fat, sleep problems, chronic stress, certain drugs, and other conditions can lower testosterone or mimic deficiency symptoms.

Evidence quality and limitations

  • Strengths: systematic reviews reduce selection bias and offer a broader view than single studies.
  • Limits: conclusions reflect the quality and design of included studies; interventions are often short, populations differ, rare harms are hard to detect, and publication bias is possible.
  • Measurement challenges: day-to-day variation, differences between labs, and assay methods complicate comparisons.
  • Our summary’s limits: the public record for this review lacks detailed numbers and inclusion criteria. We therefore avoid quantitative statements.

Practical takeaways (educational)

  • Be wary of one-size-fits-all claims; context usually determines benefit and risk.
  • Separate lab surrogates from meaningful outcomes; better numbers do not guarantee better health.
  • Prefer repeated morning tests with appropriate assays; a single outlier rarely decides anything.
  • If therapy is considered, ongoing safety checks are as important as any potential benefit.
  • Avoid self-medication and unsupervised use of hormonal products.

Sources